AUPH - Rasio Nilai Pasar marang Nilai Buku auriniapharma.com

The protection of rights for its nephritis drug and strong influence within US medicine create a robust barrier for competitors, as confirmed by this price chart where the metric stands at 3.70. Aurinia Pharmaceuticals (AUPH) generates revenue from supplying Lupkynis to clinics for the therapy of autoimmune pathologies. However, total reliance on this single product without portfolio expansion poses serious financial threats.
Aurinia Pharmaceuticals Inc (AUPH) - rincian metrik lan laporan keuangan

Aurinia Pharmaceuticals (AUPH) demonstrates low sensitivity to external shocks, supported by increasing insurance coverage and an expanding patient base for lupus nephritis. By analyzing the price-to-book ratio, investors can assess the market price premium over net assets, allowing them to determine the direction of equity revaluation and capture demand momentum before a trend reversal.